Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Study Information
Alliance Study ID: AFT-15
NCT Study ID (ClinicalTrials.gov): NCT03702725
Alliance Committee: Myeloma
Disease or Cancer Type: Multiple Myeloma & Plasma Cell Disorders
Alliance Study Chair: Yvonne A. Efebera, MD; Jacob P. Laubach, MD
Status: COMPLETED
Study Description
This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information